CareDx (CDNA) Aandelenoverzicht
CareDx, Inc. biedt oplossingen voor het verbeteren van de resultaten voor transplantatiepatiënten en het bevorderen van de gezondheid van organen in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
CDNA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CareDx, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$46.69 |
| 52 Week Hoogtepunt | US$49.76 |
| 52 Week Laag | US$11.27 |
| Bèta | 2.42 |
| 1 maand verandering | 63.77% |
| 3 maanden verandering | 118.18% |
| 1 Jaar Verandering | 296.69% |
| 3 jaar verandering | 399.63% |
| 5 jaar verandering | -34.47% |
| Verandering sinds IPO | 366.90% |
Recent nieuws en updates
Recent updates
Analyse-artikel • Aug 07
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx, Inc. ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...
Narratiefupdate • Jul 27
CDNA: Final Medicare Coverage For Transplant Testing Will Shape Balanced 2026 Repricing
Analysts have raised their fair value view on CareDx stock from $27.80 to $35.40, citing higher price targets linked to what they describe as favorable final Medicare local coverage decisions for the company’s transplant testing portfolio. Analyst Commentary Recent analyst commentary on CareDx centers on the final Medicare local coverage decisions for solid organ transplant molecular testing and what those decisions could mean for the stock’s valuation and future execution.Seeking Alpha • Jul 20
CareDx's Growth Prospects With Naveris Keep Me Bullish
Summary CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA’s AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology. However, I reckon CDNA’s valuation is relatively expensive. But despite that concern, I think its long-term growth justifies the stock as a speculative “Buy” today. Read the full article on Seeking AlphaNarratiefupdate • Jul 13
CDNA: Portfolio Shift To Oncology And Core Testing Will Shape 2026 Repricing
Analysts have adjusted their price target for CareDx to $27.80 from $25.80, citing updated assumptions around fair value and future P/E expectations. What’s in the News for CareDx CareDx completed the acquisition of Naveris, adding the NavDx blood based test for detecting molecular residual disease in HPV driven head and neck and anal cancers to its portfolio, according to recent news reports.
Narratiefupdate • Jun 29
CDNA: Clinical Data And Capital Returns Will Shape Balanced Future Upside
Analysts have nudged their CareDx fair value estimate up by $2 to $28, citing updated assumptions on growth, profitability, and future P/E as the key drivers behind the higher price target. What’s in the News for CareDx CareDx shares rose 11.5% after publication of new Kidney Allograft Outcomes AlloSure Registry data in the Journal of the American Society of Nephrology.Analyse-artikel • Jun 21
CareDx (CDNA) Stock Could Be 1.5% Overvalued After AlloSure Study Buzz
CareDx (CDNA) is back in focus after fresh data from the Kidney Allograft Outcomes AlloSure Registry and a major nephrology journal publication highlighted the clinical use of its AlloSure test for transplant monitoring. See our latest analysis for CareDx. The recent AlloSure data release and upcoming American Transplant Congress presentations appear to have coincided with building momentum in CareDx, with an 11.5% 1 day share price return and a 21.04% 30 day share price return feeding into a...
Narratiefupdate • Jun 15
CDNA: Oncology Expansion And Legal Resolution Will Shape Balanced 2026 Outlook
Analysts have raised their CareDx price target by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a modestly higher valuation. What's in the News CareDx reported Q1 revenue growth of 39% year over year, with Testing Services volume up 17%, and raised full year 2026 guidance to US$447 million to US$465 million in revenue and adjusted EBITDA of US$43 million to US$57 million, according to recent company updates.Narratiefupdate • Jun 01
CDNA: Higher 2026 Revenue Outlook And Legal Overhang Resolution Will Drive Repricing
Analysts have lifted their price target on CareDx by $1, based on updated assumptions for fair value, discount rate, revenue growth, profit margins, and a higher future P/E, as reflected in recent BTIG research. What's in the News CareDx reported that a qui tam action filed in February 2021 was dismissed by the United States District Court for the Eastern District of New York on April 23, 2026, with no monetary payment required, after the Department of Justice concluded its investigation in October 2024 without any finding of wrongdoing and declined further action.Narratiefupdate • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Narratiefupdate • Apr 13
CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.Narratiefupdate • Mar 30
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.Narratiefupdate • Mar 16
CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.Narratiefupdate • Mar 02
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.Narratiefupdate • Feb 16
CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.Narratiefupdate • Feb 01
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.Narratiefupdate • Jan 18
CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.Narratiefupdate • Jan 04
CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).Narratiefupdate • Dec 17
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).Analyse-artikel • Nov 29
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 25% gain in the last month alone...Analyse-artikel • Nov 12
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
CareDx, Inc ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...Analyse-artikel • Sep 19
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Those holding CareDx, Inc ( NASDAQ:CDNA ) shares would be relieved that the share price has rebounded 28% in the last...Analyse-artikel • Aug 27
Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Key Insights The projected fair value for CareDx is US$10.87 based on 2 Stage Free Cash Flow to Equity Current share...Narratiefupdate • Aug 15
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.Analyse-artikel • Jul 23
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
The CareDx, Inc ( NASDAQ:CDNA ) share price has fared very poorly over the last month, falling by a substantial 32...Analyse-artikel • May 02
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
Key Insights The projected fair value for CareDx is US$20.92 based on 2 Stage Free Cash Flow to Equity Current share...
Nieuw narratief • Mar 24
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.Seeking Alpha • Mar 13
CareDx: Some Litigation Clouds Have Cleared
Summary CareDx, Inc. has cleared up some litigation and legal challenges since I last looked at this diagnostic concern last summer. The company continues to post solid revenue growth and has a rock-solid balance sheet. FY2024 saw progress on numerous fronts, and CDNA delivered margin increases and a massive increase in adjusted EBITDA. An updated analysis around CareDx, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Mar 11
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
We didn't see CareDx, Inc's ( NASDAQ:CDNA ) stock surge when it reported robust earnings recently. We decided to have a...Seeking Alpha • Dec 30
CareDx: Too Risky For Me
Summary CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile. Management changes and negative employee reviews indicate potential internal instability, casting doubt on future company performance despite their innovative products. Despite strong gross margins and a solid balance sheet, CareDx's inability to turn a profit and questionable capital allocation methods make it a sell. Read the full article on Seeking AlphaAnalyse-artikel • Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
CareDx, Inc ( NASDAQ:CDNA ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Sep 29
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Summary CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. Despite ongoing legal disputes with Natera, revised processes may protect future AlloSure revenues. CDNA's valuation is high, but its expanding revenues and recent insurance coverage wins justify a "Buy" rating for investors aware of inherent biotech risks. Read the full article on Seeking AlphaAnalyse-artikel • Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 34% in the last...Rendement voor aandeelhouders
| CDNA | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -2.4% | 6.5% | 2.7% |
| 1Y | 296.7% | 41.0% | 20.9% |
Rendement versus industrie: CDNA overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 41 % opleverde.
Rendement versus markt: CDNA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 20.9 %.
Prijsvolatiliteit
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van CDNA is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van CDNA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. biedt oplossingen voor het verbeteren van de resultaten voor transplantatiepatiënten en het bevorderen van de gezondheid van organen in de Verenigde Staten en internationaal. Het bedrijf biedt AlloSure Kidney, een dd-cfDNA-oplossing (donor celvrij DNA) voor niertransplantatiepatiënten; AlloMap Heart, een oplossing voor genexpressieprofielen voor harttransplantatiepatiënten; AlloSure Heart, een dd-cfDNA-oplossing voor harttransplantatiepatiënten; en AlloSure Lung, een dd-cfDNA-oplossing voor longtransplantatiepatiënten. Het biedt ook HeartCare, dat informatie geeft over verschillende biologische processen, zoals immuunrust, actieve schade, acute cellulaire afstoting en antilichaamgemedieerde afstoting; HistoMap Kidney, een oplossing die afstoting van een allograft en het type afstoting identificeert in niertransplantatiebiopsieweefsel; en AlloHeme, een monitoringtest die terugval voorspelt bij patiënten met acute myeloïde leukemie en myelodysplastische syndromen.
CareDx, Inc. Samenvatting
| CDNA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.42b |
| Inkomsten(TTM) | US$111.01m |
| Inkomsten(TTM) | US$458.09m |
21.8x
Koers/Winstverhouding5.3x
P/S-verhoudingIs CDNA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CDNA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$458.09m |
| Kosten van inkomsten | US$134.76m |
| Brutowinst | US$323.33m |
| Overige uitgaven | US$212.32m |
| Inkomsten | US$111.01m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 2.15 |
| Brutomarge | 70.58% |
| Nettowinstmarge | 24.23% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CDNA op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/10 10:09 |
| Aandelenkoers aan het einde van de dag | 2026/08/07 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
CareDx, Inc. wordt gevolgd door 16 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |